Product liability litigation: an issue of Merck and lawsuits over Vioxx

Kurt Rotthoff

Applied Financial Economics, 2010, vol. 20, issue 24, 1867-1878

Abstract: Merck & Co., Inc. pulled Vioxx, a $2.5 billon a year nonsteroidal anti-inflammatory drug, off the shelf in September 2004. The removal followed a study that was published reporting Vioxx increased the risk of Cardiovascular Events (CE) after long-term use. In the years since then, many lawsuits have been filed against Merck. This article examines the incentive to recall a product and the effects of Merck pulling Vioxx from the shelves. Using the market's expected Internal Rate of Return (IRR) for Merck, I calculate the expected profits from future Vioxx sales. I then use data on financial effects to show how the Market Value (MV) of Merck reflects their probability of winning legal cases concerning Vioxx.

Date: 2010
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.tandfonline.com/doi/abs/10.1080/09603107.2010.526571 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:apfiec:v:20:y:2010:i:24:p:1867-1878

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/RAFE20

DOI: 10.1080/09603107.2010.526571

Access Statistics for this article

Applied Financial Economics is currently edited by Anita Phillips

More articles in Applied Financial Economics from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().